Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
05:00pm, Tuesday, 13'th May 2025
SAN FRANCISCO , May 13, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect Inv
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
10:10am, Friday, 09'th May 2025
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript
10:08pm, Thursday, 08'th May 2025
Nektar Therapeutics (NASDAQ:NKTR ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Corinne Franklin – Investor Relations Howard Robin – President and Chief Executive O
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates
07:25pm, Thursday, 08'th May 2025
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago.
Nektar Therapeutics Reports First Quarter 2025 Financial Results
04:15pm, Thursday, 08'th May 2025
SAN FRANCISCO , May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securiti
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets
06:00pm, Thursday, 01'st May 2025
SAN FRANCISCO , May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financ
Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know
11:06am, Thursday, 01'st May 2025
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?
12:30pm, Friday, 11'th Apr 2025
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
06:00pm, Thursday, 20'th Mar 2025
SAN FRANCISCO , March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & I
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
08:35am, Friday, 14'th Mar 2025
Nektar Therapeutics (NKTR) came out with quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
01:15pm, Thursday, 13'th Mar 2025
NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected.
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
09:31pm, Wednesday, 12'th Mar 2025
While the top- and bottom-line numbers for Nektar (NKTR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
09:31pm, Wednesday, 12'th Mar 2025
The headline numbers for Nektar (NKTR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript
08:00pm, Wednesday, 12'th Mar 2025
Nektar Therapeutics (NASDAQ:NKTR ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Vivian Wu - Investor Relations Howard Robin - President & Chief Executive Officer Bri
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
04:15pm, Wednesday, 12'th Mar 2025
SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable sec
